Enhance Predictive In Vivo & In Vitro Oncology Models & Optimise Model Selection Balancing Translatability, Cost & Reproducibility to Better Predict Therapeutic Response
Thank you to our speakers, sponsors, and delegates who joined us in London for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com
Welcome to the 13th Tumour Models London Summit!
With 5% of cancer drugs going into the clinic, it is critical that oncology scientists invest in more translational and predictive models to de-risk the validation of novel targets, predict therapeutic response, and support biomarker discovery, particularly with such a high price tag for clinical failure.
The 13th Tumour Models London Summit stood as the only industry-led meeting that united pharma, biotech, and preclinical CROs from Europe to network and discuss new trends and innovations in tumour models. Attracting leading preclinical and translational expertise, this forum provided an essential platform for scientists and decision makers to hear about the latest innovations in in vivo and in vitro tumour modelling to de-risk their studies and accelerate their product’s journey from lab to patient.
Featuring in-depth industry discussions and actionable case studies, this event offered a unique exploration of the most pressing topics. During the summit, our delegates...
Optimised Genomic Vendor Selection with AstraZeneca: We validated emerging genomic vendors by assessing the efficacy of various techniques to establish the most effective workflows and identify top service providers
Advanced Precision Oncology with Econic Biosciences: We identified biomarkers of resistance and response in precision oncology using mono- and co-culture patient-derived organoids and xenopgraphs
Explored Human PDC Cell-Based Cancer Vaccines with PDC*line Pharma: We delved into the therapeutic potential of human PDC cell-based cancer vaccines by examining tumour resistance, evolution, and the tumour microenvironment in humanised mouse models
Unlocked Novel Disease Insights with Digital Pathology & AI with Adaptimmune Therapeutics: We harnessed the power of digital pathology combined with AI analytics to gain groundbreaking insights into disease pathophysiology
Confidently Validated Drug Targets with 3D Models with AstraZeneca: We investigated the potential of 3D models to accurately validate drug targets and perform comprehensive preclinical safety assessments
Optimize Genomic Vendor Selection with AstraZeneca: Validate emerging genomic vendors by assessing the efficacy of various techniques to establish the most effective workflows and identify top service providers
Advance Precision Oncology with Econic Biosciences: Identify biomarkers of resistance and response in precision oncology using patient-derived organoids, comparing monoculture and co-culture models
Explore Human PDC Cell-Based Cancer Vaccines with PDC*line Pharma: Delve into the therapeutic potential of human PDC cell-based cancer vaccines by examining tumour resistance, evolution, and the tumour microenvironment in humanised mouse models
Unlock Novel Disease Insights with Digital Pathology & AI: Harness the power of digital pathology combined with AI analytics to gain groundbreaking insights into disease pathophysiology, presented by Adaptimmune Therapeutics
Confidently Validate Drug Targets with 3D Models with AstraZeneca: Investigate the potential of 3D models to accurately validate drug targets and perform comprehensive preclinical safety assessments
2024 Expert Speakers Included
2024 Partners
" This summit included the most cutting-edge achievements and potential collaborations in the scientific and industrial world "
Other Events in the Series
